PROGNOSTIC VALUE OF GENETIC VARIANTS ASSOCIATED WITH TELOMERE LENGTH IN PATIENTS WITH PROSTATE CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prostate cancer is the most common urological malignancy and the leading cause of cancer death in men worldwide. It is a heterogeneous disease with wide variability. Genomic markers, combined with clinical and pathological variables, are useful tools for reducing unnecessary biopsies, stratifying low-risk tumors from high-risk tumors, and guiding personalized treatment decisions. Variants of the TEP1 gene are of great interest as a genetic marker of the risk of developing prostate malignancies.

Full Text

Restricted Access

About the authors

V. N Pavlov

Bashkir State Medical University ofthe Ministry of Health of Russia

Email: rectorat@bashgmu.ru
Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, director, Head of Department of Urology with a course IDPO Repubhc of Bashkortostan, Ufa, Russia

M. V. Loginova

Bashkir State Medical University ofthe Ministry of Health of Russia

Email: mariialoginova25@gmail.com
Oncologist of the Oncological Department of Antitumor Drug Therapy 2, postgraduate student of the Department of Urology with the course of IDPO Repubhc of Bashkortostan, Ufa, Russia

I. R Gilyazova

Ufa Federal Research Center of the Russian Academy of Sciences

Email: gilyasova_irina@mail.ru
Candidate of Biological Sciences, docent of the Department of Medical Genetics and Fundamental Medicine, Senior Researcher Repubhc of Bashkortostan, Ufa, Russia

References

  1. Center M.M., Jemal A, Lortet-Tieulent J., Ward E., Ferlay J, Brawley O.International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6):1079-1092. doi: 10.1016/j.eururo.2012.02.054.
  2. Cooperberg M.R., Broering J.M., Carroll P.R. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101(12):878-887. doi: 10.1093/jnci/djp122.
  3. Канаева М.Д., Воробцева И.Е. Генетические маркеры предрасположенности к возникновению рака предстательной железы. Окноурология. 2015;3:16-23.
  4. Boorjian S.A., Thompson R.H., Tollefson M.K., Rangel L.J., Bergstralh E.J., Blute M.L. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011; 59(6):893-899. doi: 10.1016/j.eururo.2011.02.026.
  5. Клинические рекомендации Европейской ассоциации урологов, 2021. М., 2021.
  6. Swanson G.P., Yu C., Kattan M.W., Hermans M.R. Validation of post-operative nomograms in prostate cancer patients with long-term follow-up. Urology. 2011;78(1):105-109. doi: 10.1016/j.urology.2011.01.061.
  7. Gallagher D.J., Vijai J, Cronin A.M., Bhatia J, Vickers A.J., Gaudet M.M. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 2010;16(10):2819-2832. doi: 10.1158/1078-0432.CCR-10-0028.
  8. Brajtbord J.S., Leapman M.S., Cooperberg M.R. The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies. Eur Urol. 2017;71(15):705-709. doi: 10.1016/j.eururo.2016.08.065.
  9. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262.
  10. De Boeck G., Forsyth R.G., Praet M., Hogendoorn P.C. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol. 2009;217(3):327-344. doi: 10.1002/path.2500.
  11. Xi L., Cech T. R. Inventory of telomerase components in human cells reveals multiple subpopulations of hTR and hTERT. Nucleic Acids Res. 2014; 42(13): 8565-8577. doi: 10.1093/nar/gku560.
  12. Treat E.G., Heaphy C.M., Massie L.W., Bisoffi M., Smith A.Y., Davis M.S. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology. 2010;75(3):724- 729. doi: 10.1016/j.urology.2009.04.032.
  13. Al Olama A.A., Kote-Jarai Z., Berndt S.I. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(3):1103-1109. doi: 10.1038/ng.3094.
  14. Bojesen S.E., Pooley K.A., Johnatty S.E., Beesley J., Michailidou K., Tyrer J.P. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013; 45(4):371-384. doi: 10.1038/ng.2566.
  15. Sun Y., Tao W., Huang M., Wu X., Gu J. Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome. J Cell Mol Med. 2017;21(3):510-518. doi: 10.1111/jcmm.12995.
  16. Pellatt A.J., Wolff R.K., Torres-Mejia G., John E.M., Herrick J.S., Lundgreen A. Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study. Genes Chromosomes Cancer. 2013; 52(7):595-609. doi: 10.1002/gcc.22056.
  17. Bhattacharyya S., Keirsey J., Russell B., Kavecansky J., Lillard-Wetherell K., Tahmaseb K. Telomerase-associated protein 1, HSP90, and topoisomerase II alpha associate directly with the BLM helicase in immortalized cells using ALT and modulate its helicase activity using telomeric DNA substrates. J Biol Chem. 2009;284(2):14966-14977. doi: 10.1074/jbc.M900195200.
  18. Jung S.W., Park N.H., Shin J.W., Park B.R., Kim C.J., Lee J.E. Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients with chronic Hepatitis B. Hepatology. 2014;59(5): 1912-1920. doi: 10.1002/hep.26655.
  19. Zhao J., Stockwell T., Roemer A., Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16(1):845-858. doi: 10.1186/s12885-016-2891-z.
  20. Chang J., Dinney C.P., Huang M., Wu X., Gu J. Genetic variants in telomeremaintenance genes and bladder cancer risk. PLoS One. 2012;7(2): e30665. doi: 10.1371/journal.pone.0030665.
  21. Meeker A.K. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol. 2006;24(2):122-130. doi: 10.1016/j.urolonc.2005.11.002.
  22. Shammas M.A. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care. 2011;14(1):28-34. doi: 10.1097/MCO.0b013e32834121b1.
  23. Bernardes de Jesus B., Blasco M.A. Telomerase at the intersection of cancer and aging. Trends Genet. 2013;29(9):513-520. doi: 10.1016/j.tig.2013.06.007.
  24. Kroupa M., Rachakonda S.K., Liska V., Srinivas N., Urbanova M., Jiraskova K., Schneiderova M., Vycital O., Vymetalkova V., Vodickova L., Kumar R., Vodicka P. Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis. Br J Cancer. 2019;121(4):344-350. doi: 10.1038/s41416-019-0525-3.
  25. Savage S.A., Chanock S.J., Lissowska J., Brinton L.A., Richesson D., Peplonska B., Bardin-Mikolajczak A., Zatonski W., Szeszenia-Dabrowska N., Garcia-Closas M. Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer. 2007;97(6):832-836. doi: 10.1038/sj.bjc.6603934.
  26. Sethi I., Bhat G.R., Singh V., Kumar R., Bhanwer A.J., Bamezai R.N., Sharma S., Rai E. Role of telomeres and associated maintenance genes in Type 2 Diabetes Mellitus: A review. Diabetes Res Clin Pract. 2016; 122:92-100. doi: 10.1016/j.diabres.2016.10.015.
  27. Borque Â., del Amo J., Esteban L.M., Ars E., Hernandez C., Planas J., Arruza A., Llarena R., Palou J., Herranz F., Raventos C.X., Tejedor D., Artieda M., Simon L., Martinez A., Carceller E., Suarez M., Allué M., Sanz G., Morote J. Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int. 2013;111(4):549-558. doi: 10.1111/j.1464-410X.2012.11333.x.
  28. Patel A.R., Stephenson A.J. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol. 2011 ;8(7):385-392. doi: 10.1038/nrurol.2011.80.
  29. Morote J., Del Amo J., Borque A, Ars E., Hernandez C., Herranz F. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol. 2010; 184(2):506-511. doi: 10.1016/j.juro.2010.03.144.
  30. Szaflarski W., Sujka-Kordowska P., Pula B., Jaszczynska-Nowinka K., Andrzejewska M., Zawierucha P. Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.Int. J. Oncol. 2013;43(2):513-520. doi: 10.3892/ijo.2013.1975.
  31. Mirabelle L., Huang W.Y., Wong J.Y., Chatterjee N., Reding D., Crawford E.D. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell. 2009; 8(): 405-413. Doi: 10.111 l/j. 1474-9726.2009.00485.X.
  32. Kote-Jarai Z., Saunders E.J., Leongamornlert D.A., Tymrakiewicz M., Dadaev T., Juggmauth-Little S. Fine-mapping identifies multiple prostate cancer risk loci at 5pl5, one of which associates with TERT expression. Hum Mol Genet. 2013; 22(12): 2520-2528. doi: 10.1093/hmg/ddt086.
  33. Babizhayev M.A., Savelyeva E.L., Moskvina S.N., Yegorov Y.E. Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther. 201 l;18(6):e209-e226. doi: 10.1097/MJT.0b013e3181cf8ebb.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies